Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||LY2090314 + Niraparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LY2090314||LY-2090314|LY 2090314||GSK3 Inhibitor (Pan) 3||LY2090314 inhibits glycogen synthase kinase 3 (GSK3), therefore activates Wnt signaling pathway and leads to apoptosis in tumor cells (PMID: 25915038, PMID: 26735141, PMID: 32391602).|
|Niraparib||Zejula||MK4827||PARP Inhibitor (Pan) 22||Zejula (niraparib) binds and inhibits PARP, which may result in accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved as maintenance therapy in patients with recurrent or newly-diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy, and in ovarian, fallopian tube, or primary peritoneal cancer that received 3 or more chemotherapies and is homologous recombination deficient as indicated by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and progressed 6 months or more after response to last platinum-based chemotherapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||LY2090314 + Niraparib||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with LY2090314 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Zejula (niraparib) in culture, resulting in a synergistic effect (PMID: 33589588).||33589588|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|